Clinical Research Studies

The purpose of this research study, is to determine if TAK-935 is safe and working well in reducing seizure frequency in males and females with 15q duplication syndrome or CDKL5 deficiency disorder, already being treated with other anti-epileptic drugs (AEDs), and aged 2 to 35. TAK-935 is an investigational drug and has not been approved by any regulatory agency for use outside of a research study. TAK-935 is being studied as a new treatment for epileptic diseases. TAK-935 has been tested previously in animal models and showed capacity to reduce seizures; it has also been tested on healthy subjects and showed to be safe and well tolerated. Additionally, TAK-935 is being tested in adults affected by developmental epileptic encephalopathies (DEEs).